

***** Welcome to STN International *****

NEWS 1 Web Page for STN Seminar Schedule - N.
America
NEWS 2 AUG 10 Time limit for inactive STN sessions doubles
to 40 minutes
NEWS 3 AUG 18 COMPENDEX indexing changed for the
Corporate Source (CS) field
NEWS 4 AUG 24 ENCOMPAT/ENCOMPAT2 reloaded and
enhanced
NEWS 5 AUG 24 CA/Caplus enhanced with legal status
information for U.S. patents
NEWS 6 SEP 09 50 Million Unique Chemical Substance
Recorded in CAS REGISTRY
NEWS 7 SEP 11 WPIDS, WPINDEX, and WPX now include
Japanese FTERM thesaurus
NEWS 8 OCT 21 Derwent World Patents Index Coverage of
Indian and Taiwanese Content Expanded
NEWS 9 OCT 21 Derwent World Patents Index enhanced with
human translated claims for Chinese Applications and
Utility Models
NEWS 10 OCT 27 Free display of legal status information in
CA/Caplus, USPATFULL, and USPAT2 in the month of
November.

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS
V8.4, AND CURRENT DISCOVER FILE IS DATED 06 APRIL
2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news
on that specific topic.

All use of STN is subject to the provisions of the STN customer
agreement. This agreement limits use to scientific research.
Use
for software development or design, implementation of
commercial
gateways, or use of CAS and STN data in the building of
commercial
products is prohibited and may result in loss of user privileges
and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 14:20:09 ON 28 OCT 2009

=> file caplus
COST IN U.S. DOLLARS SINCE FILE
TOTAL ENTRY SESSION
FULL ESTIMATED COST 0.66 0.66

FILE 'CAPLUS' ENTERED AT 14:21:57 ON 28 OCT 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER
AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERI CAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is

held by the publishers listed in the PUBLISHER (PB) field
(available
for records published or updated in Chemical Abstracts after
December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in
searching
databases on STN. Any dissemination, distribution, copying, or
storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 28 Oct 2009 VOL 151 SS 18
FILE LAST UPDATED: 27 Oct 2009 (20091027/ED)
REVISED CLASS FIELDS ('NCL') LAST RELOADED: Aug 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE
Aug 2009

Caplus now includes complete International Patent Classification
(IPC)
reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s tr1 or (tr(w1))/bi,ab
UNMATCHED RIGHT PARENTHESIS '1')/Bi,AB'
The number of right parentheses in a query must be equal to the
number of left parentheses.

=> s (tr1 or (tr(w1))/bi,ab 1091 TR1/Bl 959
TR1/AB 18826 TR1/Bl 16344 TR/AB
10376955 1/Bl 9444959 1/AB 821
TR(W)1
L1 1884 (TR1 OR (TR(W1))/Bi,AB

=> s (cd18 or (cd(w)18) or (cd49b)) or (cd(w)49b)/bi,ab
5386 CD18/Bl 4147 CD18/AB 326706
CD/Bl 270656 CD/AB 931073 18/Bl
852118 18/AB 182 CD(W)18 158 CD49B/Bl
142 CD49B/AB 326706 CD/Bl 270656
CD/AB 106 49B/Bl 90 49B/AB
1 CD(W)49B
L2 5657 (CD18 OR (CD(W)18) OR (CD49B) OR
(CD(W)49B))/Bi,AB

=> s l1 and l2
L3 4 L1 AND L2

=> d his
'FILE 'HOME' ENTERED AT 14:20:09 ON 28 OCT 2009'
FILE 'CAPLUS' ENTERED AT 14:21:57 ON 28 OCT 2009
L1 1884 S (TR1 OR (TR(W)1))/Bi,AB
L2 5657 S (CD18 OR (CD(W)18) OR (CD49B) OR
(CD(W)49B))/Bi,AB
L3 4 S L1 AND L2

=> d l3 1-4 bib ab

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2009:1224075 CAPLUS <<LOGIN ID::20091028>>

TI Increased expression of regulatory ***Tr1*** cells in recurrent hepatitis C after liver transplantation
AU Carpenter, A.; Conti, F.; Stenard, F.; Aoudjehane, L.; Miroux, C.; Podevin, P.; Morales, O.; Chouzenoux, S.; Scatton, O.; Groux, H.; Auriat, C.; Calmus, Y.; Pancre, V.; Delhem, N.
CS Laboratoire de Biologie Cellulaire, Universite Rene Descartes, Paris, Fr.
SO American Journal of Transplantation (2009), 9(9), 2102-2112 CODEN: AJTMBR; ISSN: 1600-6135
PB Wiley-Blackwell
DT Journal
LA English
AB Immune response failure during HCV infection has been associated with the activity of regulatory T cells. Hepatitis C-related cirrhosis is the main reason for liver transplantation. However, 80% of transplanted patients present an accelerated recurrence of the disease. This study assessed the involvement of regulatory T-cell subsets (CD4+CD25+ cells: 'Treg' and ***CD196*** + ***CD18*** + cells: 'T regulatory-1' cells), in the recurrence of HCV after liver transplantation, using transcriptomic analysis, ELISA assays on serum samples and immunohistochemistry on liver biopsies from liver recipients 1 and 5 years after transplantation. Three groups of patients were included: stable HCV-neg. recipients and those with mild and severe hepatitis C recurrence. At 5 years, Treg markers were overexpressed in all HCV+ recipients. By contrast, ***Tr1*** markers were only overexpressed in patients with severe recurrence. At 1 year, a trend toward the overexpression of ***Tr1*** was noted in patients evolving toward severe recurrence. IL-10 production, a characteristic of the ***Tr1*** subset, was enhanced in severe recurrence at both 1 and 5 years. These results suggest that ***Tr1*** are enhanced during severe HCV recurrence after liver transplantation and could be predictive of HCV recurrence. High levels of IL-10 at 1 year could be predictive of severe recurrence, and high IL-10 producers might warrant more intensive management.

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN AN 2006:167774 CAPLUS <<LOGINID::20091028>>

DN 144-231482

TI Regulatory T-cells for use in atherosclerosis therapy

IN Groux, Herve; Tedgui, Alain; Mallat, Ziad; Brun, Valerie
PA Institut National de la Sante et de la Recherche Medicale (INSERM), Fr.; Txell

SO PCT Int. Appl., 39 pp. CODEN: PXXXD2

DT Patent

LA English

FAN,CNT 1 PATENT NO. KIND DATE APPLICATION NO. DATE -----

PI WO 2006018674 A1 20060223 WO 2004-IB2858
20040811 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR,
BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ,
EG, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,
MA, MD, MG, MK, MN, MW, MZ, NA, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, RW,
AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI,
GM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE,
LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM CA 2575689 A1 20060223
CA 2004-2575689 20040811 US 20080107663 A1
20080508 US 2007-660113 20070905
PRAI WO 2004-IB2858 W 20040811

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The authors disclose a method of treating or preventing atherosclerosis comprising (a) an antigen which has been used to activate in vitro a ***Tr1*** cell population and (b) administration of the ***Tr1*** cell population activated. In one example, the authors demonstrate a reduction in atherosclerotic plaque size in ovalbumin-sensitized apoE-knockout mice receiving ovalbumin-specific ***Tr1*** cells.

OSC G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

RE,CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE REFORMAT

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN AN 2005:451235 CAPLUS <<LOGINID::20091028>>
DN 142:457076

TI Use of lipopeptides for activating T lymphocytes through the skin, and therapeutic use

IN Groux, Herve; Brun, Valerie; Foussat, Arnaud
PA Txell, Fr.; Institut National de la Sante et de la Recherche Medicale INSERM

SO PCT Int. Appl., 38 pp. CODEN: PXXXD2

DT Patent

LA English

FAN,CNT 1 PATENT NO. KIND DATE APPLICATION NO. DATE -----

PI WO 2005046729 A2 20050526 WO 2004-IB3882
20041105 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR,
BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ,
EG, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,
MA, MD, MG, MK, MN, MW, MZ, NA, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, RW,
AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI,
GM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE,
LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM CA 2575689 A1 20040811 US 2004288646
A1 20050526 AU 2004-288646 20041105 CA 2545841
A1 20050526 CA 2004-2545841 20041105 EP 1689440
A2 20060816 EP 2004-798985 20041105 R: AT, BE,
CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE, MC, PT, IE,
SI, LT, LV, R, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,
HR, IS US 20072075005 A1 20071129 US 2007-579078
20070616

PRAI FR 2003-13261 A 20031112 WO 2004-IB3882

W 20041105

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention discloses the use of a method for treating or preventing skin diseases and diseases of the mucosa, comprising administering topically to a mammal in need of such a treatment a topical medicinal product comprising a lipopeptide or a mixt. thereof, wherein the lipopeptide comprises a peptide antigen specific for a T cell population, the peptide antigen being coupled covalently with a lipid radical and being capable of activating the T cell population. Such a use is more specifically intended for a transcutaneous application of the topical medicinal product, which is advantageously intended to prevent or treat a skin disease. The invention also relates to pharmaceutical or cosmetic formulations comprising the lipopeptide.

OSC G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS ON STN AN 2005:618 CAPLUS <<LOGID:20091028>

DN 142:73419

TI Method for identification of ****TR1**** regulator lymphocytes by the presence and the expression of specific molecules, and diagnostic and therapeutic applications

IN Groux, Hervé

PA Tixel, Fr.

SO Fr. Demande, 89 pp. CODEN: FRIXXBL

DT Patent

LA French

FAN.CNT 1 PATENT NO. KIND DATE APPLICATION NO. DATE -----

PI FR 2856700 A1 20041231 FR 2003-7601
20030624 FR 2856700 B1 20070603 AU 2004251462
A1 20050106 AU 2004-251462 20040624 CA 2529941
A1 20050106 CA 2004-2529941 20040624 WO
2005000344 A2 20050106 WO 2004-FR1583
20040624 WO 200500344 A3 20050609 W: AE, AG,
AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA,
SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB,
GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, OM, GA, GN, GO, GW, ML, MR, NE, SN, TD,
TG EP 1660118 A2 20060531 EP 2004-767439
20040624 EP 1660118 B1 20080409 R: AT, BE, CH,
DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI,
FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK JP 2007520197 T
20070726 JP 2006-516319 20040624 AT 391513
T 20080415 AT 2004-767439 20040624 ES 2305836
T3 20081101 ES 2004-767439 20040624
PRAI FR 2003-7601 A 20030624 WO 2004-FR1583
W 20040624

AB The invention discloses a method for the identification of ***TR1**** regulator lymphocytes in a biol. sample based on the defin. of the simultaneous presence of CD4, ***CD18*** and/or CD11a, ***CD49b*** and, if necessary, by the description of a overexpression of genes coding for the mols. CD4, PSGL-1, PECAM-1 and .alpha.V/.beta.3. The invention also discloses a method for quantification and a method for diagnosis of autoimmune or inflammatory diseases based on the aforementioned process of identification. The invention further discloses a method for enrichment of ***TR1**** regulator lymphocytes based on the defin. of the simultaneous presence of these mols. The invention also discloses the use of a compn. so enriched for the treatment by an autoimmune or inflammatory disease, in particular Crohn's disease.

OSC G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 14:20:09 ON 28 OCT 2009)

FILE 'CAPLUS' ENTERED AT 14:21:57 ON 28 OCT 2009

L1 1884 S (TR1 OR (TR(W1))/BI,AB

L2 5657 S (CD18 OR (CD(W1)18) OR (CD49B) OR

(CD(W)49B)/BI,AB

L3 4 S L1 AND L2

=> log y

COST IN U.S. DOLLARS

TOTAL

SINCE FILE

ENTRY SESSION

53.82 54.48

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE

FILE TOTAL ENTRY

SESSION

CA SUBSCRIBER PRICE

-3.28 -3.28

STN INTERNATIONAL LOGOFF AT 14:23:48 ON 28 OCT 2009